Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
about
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerOsimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyOvercoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.EGFR T790M: revealing the secrets of a gatekeeper.Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.Understanding and targeting resistance mechanisms in NSCLC.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors.The role of brigatinib in crizotinib-resistant non-small cell lung cancer.Third generation EGFR TKIs: current data and future directions.Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.Targeted drugs for systemic therapy of lung cancer with brain metastases.[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].Controllable extension of hairpin-structured flaps to allow low-background cascade invasive reaction for a sensitive DNA logic sensor for mutation detection.[Aberrant Expression of Rb and pRb-780, pRb-795 in Lung Adenocarcinoma Patients with EGFR Mutations and Their Clinical Significance].Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design.First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?Elucidation of the critical epitope of an anti-EGFR monoclonal antibody EMab-134.Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy.Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspectiveQ58714439Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and -C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case reportPersonalized therapy for lung cancer: Striking a moving target
P2860
Q33740707-BC436C86-A060-4BDC-B99E-6A4C37EC4BABQ38598893-E973BB87-B6F3-4F54-A8E1-BDDC21CBFEF0Q38682189-E6C2A745-E6B4-417E-8CC0-D4FC439AA8C5Q42701535-41F55FF4-82BD-4D75-A2DE-9450E91149E8Q46071509-CBA5B354-01FD-437B-8B90-C62DE258C61AQ46915997-7D417D3B-78A2-4223-BDA4-499058699EFAQ47146662-B2942952-684E-47E0-82C4-1431BD382495Q48231295-91469117-8A7D-41CB-BA8D-89E7FE83A449Q48507354-33B46717-41E8-4107-B244-D53E983D38C4Q48512265-93F62975-B6B5-49DA-8AE7-0DBCBCDD5F7FQ49887956-704C22B6-9609-47E1-8C21-DD2667AB2563Q50040968-00509051-3852-4771-87AB-A4042F33BDBBQ50052820-6420D93D-3194-436D-8695-C6F2C6D464B4Q51741619-8F998076-3DC9-46B2-888A-032F9D4C29CCQ52575929-8576D4D5-6753-46F8-8ABD-55D743DBD93CQ52769484-54E35383-BD51-47A4-AB3E-BC5916B20219Q53111572-65B46FFA-5710-4563-B34B-E2F3CF55B836Q54110124-7EE8FF90-EB6C-4870-BBF0-1709419B6932Q54976917-ADE621A9-27A7-477E-AF68-D866ACAEA75CQ54977126-6D5EEC11-52F3-42C2-B97B-8713B6679373Q55191884-833F3070-ACCA-4BA7-8F85-31962CB07B48Q55445439-B3584770-137A-4B85-971D-022BC05722F9Q57174988-AC4DFCC4-9A8D-4ED7-9A10-ADFFC4BA60A5Q57177486-EF9D63B1-CD22-4FBE-9A4D-A5DE42DA84F6Q58714439-F5FCA30C-BE12-4081-AE16-D669B1EFCA21Q58761509-FB0E3FF8-6C0B-4EA3-8D09-F010FD6E66BAQ58792324-8D65AB21-BD6D-4351-8C11-2A2BA845B019
P2860
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Brigatinib combined with anti- ...... ed non-small-cell lung cancer.
@en
Brigatinib combined with anti- ...... ed non-small-cell lung cancer.
@nl
type
label
Brigatinib combined with anti- ...... ed non-small-cell lung cancer.
@en
Brigatinib combined with anti- ...... ed non-small-cell lung cancer.
@nl
prefLabel
Brigatinib combined with anti- ...... ed non-small-cell lung cancer.
@en
Brigatinib combined with anti- ...... ed non-small-cell lung cancer.
@nl
P2093
P2860
P356
P1476
Brigatinib combined with anti- ...... ted non-small-cell lung cancer
@en
P2093
Ken Uchibori
Mayumi Kamada
Mitsugu Araki
Naohiko Inase
Naoya Fujita
Shigeo Sato
Yasushi Okuno
P2860
P2888
P356
10.1038/NCOMMS14768
P407
P577
2017-03-13T00:00:00Z